{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:26:07Z","timestamp":1792031167295,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11538-021-00869-5","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T09:03:45Z","timestamp":1616144625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Modeling CAR T-Cell Therapy with Patient Preconditioning"],"prefix":"10.1007","volume":"83","author":[{"given":"Katherine","family":"Owens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2761-825X","authenticated-orcid":false,"given":"Ivana","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"869_CR1","doi-asserted-by":"crossref","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC (2016) CAR T cell therapy: a game changer in cancer treatment. J Immunol Res","DOI":"10.1155\/2016\/5474602"},{"key":"869_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biosystems.2013.12.001","volume":"116","author":"FS Borges","year":"2014","unstructured":"Borges FS, Iarosz K, Ren HP, Batista AM, Baptista MS, Viana RL, Lopes S, Grebogi C (2014) Model for tumour growth with treatment by continuous and pulsed chemotherapy. Biosystems 116:43\u201348","journal-title":"Biosystems"},{"issue":"10","key":"869_CR3","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","volume":"81","author":"R Brady","year":"2019","unstructured":"Brady R, Enderling H (2019) Mathematical models of cancer: When to predict novel therapies, and when not to. Bull Math Biol 81(10):3722\u20133731","journal-title":"Bull Math Biol"},{"issue":"2","key":"869_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","volume":"19","author":"CE Brown","year":"2019","unstructured":"Brown CE, Mackall CL (2019) CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol 19(2):73","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"869_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11538-010-9526-3","volume":"73","author":"R Eftimie","year":"2011","unstructured":"Eftimie R, Bramson JL, Earn DJ (2011) Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol 73(1):2\u201332","journal-title":"Bull Math Biol"},{"issue":"5","key":"869_CR6","first-page":"1417","volume":"60","author":"SN Gardner","year":"2000","unstructured":"Gardner SN (2000) A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res 60(5):1417\u20131425","journal-title":"Cancer Res"},{"issue":"4","key":"869_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cts.12636","volume":"12","author":"D Hardiansyah","year":"2019","unstructured":"Hardiansyah D, Ng CM (2019) Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy. Clin Transl Sci 12(4):343\u2013349","journal-title":"Clin Transl Sci"},{"issue":"7","key":"869_CR8","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077\u20133085","journal-title":"Cancer Res"},{"issue":"3","key":"869_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","volume":"200","author":"DT Harris","year":"2018","unstructured":"Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, Lever M, Dushek O, Schmitt TM, Greenberg PD et al (2018) Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J Immunol 200(3):1088\u20131100","journal-title":"J Immunol"},{"issue":"17","key":"869_CR10","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS et al (2019) The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR t cells. Blood 133(17):1876\u20131887","journal-title":"Blood"},{"issue":"19","key":"869_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ifacol.2018.09.039","volume":"51","author":"B Hopkins","year":"2018","unstructured":"Hopkins B, Tucker M, Pan Y, Fang N, Huang Z (2018) A model-based investigation of cytokine storm for T-cell therapy. IFAC-PapersOnline 51(19):76\u201379","journal-title":"IFAC-PapersOnline"},{"issue":"5161","key":"869_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1126\/science.7513904","volume":"264","author":"A Huang","year":"1994","unstructured":"Huang A, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264(5161):961\u2013965","journal-title":"Science"},{"key":"869_CR13","doi-asserted-by":"crossref","unstructured":"Itzhaki O, Jacoby E, Nissani A, Levi M, Nagler A, Kubi A, Brezinger K, Brayer H, Zeltzer La, Rozenbaum M, et\u00a0al. (2020) Head-to-head comparison of in-house produced CD19 CAR T-cell in ALL and NHL patients. J Immunother Cancer 8(1)","DOI":"10.1136\/jitc-2019-000148"},{"issue":"1","key":"869_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02235-w","volume":"18","author":"NA Jorge","year":"2020","unstructured":"Jorge NA, Cruz JG, Pretti MAM, Bonamino MH, Possik PA, Boroni M (2020) Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment. J Transl Med 18(1):1\u201317","journal-title":"J Transl Med"},{"key":"869_CR15","doi-asserted-by":"crossref","unstructured":"Ju HY, Lee JW, Hong CR, Kim H, Park KD, Shin HY, Kim S, Jang K, Yu KS, Jang IJ, et\u00a0al. (2014) Pharmacokinetics of fludarabine in pediatric hematopoietic stem cell transplantation","DOI":"10.1182\/blood.V124.21.2466.2466"},{"issue":"1","key":"869_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. New England J Med 379(1):64\u201373","journal-title":"New England J Med"},{"key":"869_CR17","doi-asserted-by":"crossref","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73","DOI":"10.1126\/scitranslmed.3002842"},{"issue":"5","key":"869_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13(5):273","journal-title":"Nat Rev Clin Oncol"},{"key":"869_CR19","unstructured":"Kimmel GJ, Locke FL, Altrock PM (2019) Evolutionary dynamics of CAR T cell therapy. BioRxiv 717074"},{"issue":"3","key":"869_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s002850050127","volume":"37","author":"D Kirschner","year":"1998","unstructured":"Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37(3):235\u2013252","journal-title":"J Math Biol"},{"key":"869_CR21","unstructured":"Kite (2017) Yescarta (axicabtagene ciloleucel) highlights of prescribing information. https:\/\/www.fda.gov\/media\/108377\/download"},{"issue":"20","key":"869_CR22","first-page":"4099","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DAN, Lanier BJ et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood J Am Soc Hematol 116(20):4099\u20134102","journal-title":"Blood J Am Soc Hematol"},{"key":"869_CR23","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM et al (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35(16):2017","DOI":"10.1200\/JCO.2016.71.3024"},{"issue":"1","key":"869_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, Dhaese JG, Schloesser H et al (2019) Advances in cancer immunotherapy 2019-latest trends. J Exp Clin Cancer Res 38(1):268","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"869_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8240(05)80260-5","volume":"56","author":"VA Kuznetsov","year":"1994","unstructured":"Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56(2):295\u2013321","journal-title":"Bull Math Biol"},{"issue":"1","key":"869_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D et al (2019) Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45\u201363","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"869_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin 69(5):363\u2013385","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"869_CR28","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022","journal-title":"Oncotarget"},{"key":"869_CR29","doi-asserted-by":"crossref","unstructured":"Nanda S, de\u00a0Pillis LG, Radunskaya AE (2013) B cell chronic lymphocytic leukemia-a model with immune response","DOI":"10.3934\/dcdsb.2013.18.1053"},{"issue":"17","key":"869_CR30","first-page":"1799","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS (2019) CAR T efficacy: Is conditioning the key? Blood J Am Soc Hematol 133(17):1799\u20131800","journal-title":"Blood J Am Soc Hematol"},{"key":"869_CR31","unstructured":"Novartis (2017) Kymriah (tisagenlecleucel) highlights of prescribing information. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert---KYMRIAH.pdf"},{"issue":"7","key":"869_CR32","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK (2017) Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171(7):1678\u20131691","journal-title":"Cell"},{"key":"869_CR33","doi-asserted-by":"crossref","unstructured":"Pandya PH, Murray ME, Pollok KE, Renbarger JL (2016) The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res","DOI":"10.1155\/2016\/4273943"},{"issue":"2","key":"869_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","volume":"26","author":"D Pettitt","year":"2018","unstructured":"Pettitt D, Arshad Z, Smith J, Stanic T, Holl\u00e4nder G, Brindley D (2018) CAR T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther 26(2):342\u2013353","journal-title":"Mol Ther"},{"issue":"17","key":"869_CR35","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1158\/0008-5472.CAN-05-0564","volume":"65","author":"LG de Pillis","year":"2005","unstructured":"de Pillis LG, Radunskaya AE, Wiseman CL (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65(17):7950\u20137958","journal-title":"Cancer Res"},{"issue":"4","key":"869_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jtbi.2005.06.037","volume":"238","author":"LG de Pillis","year":"2006","unstructured":"de Pillis LG, Gu W, Radunskaya AE (2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 238(4):841\u2013862","journal-title":"J Theor Biol"},{"issue":"7\u20138","key":"869_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0895-7177(02)00227-3","volume":"36","author":"STRd Pinho","year":"2002","unstructured":"Pinho STRd, Freedman H, Nani F (2002) A chemotherapy model for the treatment of cancer with metastasis. Math Comput Model 36(7\u20138):773\u2013803","journal-title":"Math Comput Model"},{"issue":"18","key":"869_CR38","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1158\/1078-0432.CCR-12-0084","volume":"18","author":"B Ribba","year":"2012","unstructured":"Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, \u010cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L et al (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18(18):5071\u20135080","journal-title":"Clin Cancer Res"},{"key":"869_CR39","doi-asserted-by":"crossref","unstructured":"Rodrigues BJ, Barros LRC, Almeida RC (2019) Three-compartment model of CAR T-cell immunotherapy. BioRxiv 779793","DOI":"10.1101\/779793"},{"key":"869_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00057","volume":"3","author":"JA Rohrs","year":"2019","unstructured":"Rohrs JA, Wang P, Finley SD (2019) Understanding the dynamics of T-cell activation in health and disease through the lens of computational modeling. JCO Clin Cancer Inform 3:1\u20138","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"869_CR41","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3109\/10428194.2015.1110746","volume":"57","author":"K R\u00f6sch","year":"2016","unstructured":"R\u00f6sch K, Scholz M, Hasenclever D (2016) Modeling combined chemo-and immunotherapy of high-grade non-hodgkin lymphoma. Leukemia & Lymphoma 57(7):1697\u20131708","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"869_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299\u2013308","journal-title":"Nat Rev Cancer"},{"issue":"162","key":"869_CR43","doi-asserted-by":"publisher","first-page":"20190734","DOI":"10.1098\/rsif.2019.0734","volume":"17","author":"P Sahoo","year":"2020","unstructured":"Sahoo P, Yang X, Abler D, Maestrini D, Adhikarla V, Frankhouser D, Cho H, Machuca V, Wang D, Barish M et al (2020) Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. J R Soc Interface 17(162):20190734","journal-title":"J R Soc Interface"},{"key":"869_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Ann Rev Immunol 27:591\u2013619","journal-title":"Ann Rev Immunol"},{"issue":"Supplement 1","key":"869_CR45","first-page":"2561","volume":"130","author":"AM Stein","year":"2017","unstructured":"Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, June CH, Tomassian L et al (2017) CTL019 model-based cellular kinetic analysis of chimeric antigen receptor (CAR) T cells to characterize the impact of tocilizumab on expansion and to identify correlates of cytokine release syndrome severity. Blood 130(Supplement 1):2561","journal-title":"Blood"},{"issue":"5","key":"869_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/psp4.12388","volume":"8","author":"AM Stein","year":"2019","unstructured":"Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S et al (2019) Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharm Syst Pharmacol 8(5):285\u2013295","journal-title":"CPT Pharm Syst Pharmacol"},{"issue":"5","key":"869_CR47","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s11538-017-0263-8","volume":"80","author":"A Talkington","year":"2018","unstructured":"Talkington A, Dantoin C, Durrett R (2018) Ordinary differential equation models for adoptive immunotherapy. Bull Math Biol 80(5):1059\u20131083","journal-title":"Bull Math Biol"},{"issue":"4","key":"869_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T cell dysfunction in cancer. Cancer Cell 33(4):547\u2013562","journal-title":"Cancer Cell"},{"issue":"6","key":"869_CR49","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM et al (2016) CD19 CAR T cells of defined CD4+: CD8+ composition in adult b cell all patients. J Clin Investig 126(6):2123\u20132138","journal-title":"J Clin Investig"},{"issue":"9","key":"869_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0898-1221(94)00179-0","volume":"28","author":"J Usher","year":"1994","unstructured":"Usher J (1994) Some mathematical models for cancer chemotherapy. Comput Math Appl 28(9):73\u201380","journal-title":"Comput Math Appl"},{"issue":"5","key":"869_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","volume":"10","author":"J Villanueva","year":"2008","unstructured":"Villanueva J, Herlyn M (2008) Melanoma and the tumor microenvironment. Curr Oncol Rep 10(5):439\u2013446","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"869_CR52","doi-asserted-by":"publisher","first-page":"1901829","DOI":"10.1002\/advs.201901829","volume":"6","author":"X Wang","year":"2019","unstructured":"Wang X, Scarf\u00f2 I, Schmidts A, Toner M, Maus MV, Irimia D (2019) Dynamic profiling of antitumor activity of CAR T cells using micropatterned tumor arrays. Adv Sci 6(23):1901829","journal-title":"Adv Sci"},{"key":"869_CR53","volume-title":"Introduction to applied nonlinear dynamical systems and chaos","author":"S Wiggins","year":"2003","unstructured":"Wiggins S (2003) Introduction to applied nonlinear dynamical systems and chaos, vol 2. Springer, Berlin"},{"issue":"2","key":"869_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/bjc.2016.171","volume":"115","author":"Y Yamamoto","year":"2016","unstructured":"Yamamoto Y, Offord CP, Kimura G, Kuribayashi S, Takeda H, Tsuchiya S, Shimojo H, Kanno H, Bozic I, Nowak MA et al (2016) Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer 115(2):195\u2013202","journal-title":"Br J Cancer"},{"issue":"20","key":"869_CR55","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","volume":"66","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM (2006) Attenuation of CD8+ T-cell function by CD4+ CD25+ regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma. Cancer Res 66(20):10145\u201310152","journal-title":"Cancer Res"},{"key":"869_CR56","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","volume":"4","author":"G Zhang","year":"2014","unstructured":"Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y et al (2014) Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep 4:3571","journal-title":"Sci Rep"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-021-00869-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11538-021-00869-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-021-00869-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T09:13:12Z","timestamp":1667034792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11538-021-00869-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1007\/s11538-021-00869-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.20.162925","asserted-by":"object"}]},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"42"}}